Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19-associated psychosis: A systematic review of case reports

Colin M. Smith\textsuperscript{a,b,*}, Elizabeth B. Gilbert\textsuperscript{a,b}, Paul A. Riordan\textsuperscript{b,c}, Nicole Helmke\textsuperscript{a,b}, Megan von Isenburg\textsuperscript{d}, Brian R. Kincaid\textsuperscript{a,b}, Kristen G. Shirey\textsuperscript{a,b}

\textsuperscript{a} Department of Medicine, Duke University School of Medicine, Durham, NC, USA
\textsuperscript{b} Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
\textsuperscript{c} Department of Psychiatry, Durham Veteran Affairs Medical Center, Durham, NC, USA
\textsuperscript{d} Duke University Medical Center Library, Duke University Medical Center, Durham, NC, USA

\textsuperscript{*} Corresponding author at: Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 2301 Erwin Road, Durham, NC 27710, USA.
E-mail address: colin.smith@duke.edu (C.M. Smith).

Abstract

Objective: To describe the comorbidities, presentations, and outcomes of adults with incident psychosis and a history of COVID-19.

Methods: We completed a descriptive systematic review of case reports according to PRISMA guidelines, including cases of adult patients with incident psychosis and antecedent or concurrent COVID-19. We extracted patient demographics, comorbidities, clinical course, and outcomes, and assessed cases for quality using a standardized tool.

Results: Of 2396 articles, we included 40 reports from 17 countries, comprising 48 patients. The mean age of patients was 43.9 years and 29 (60%) were males. A total of 7 (15%) had a documented psychiatric history, 6 (13%) had a substance use history and 11 (23%) had a comorbid medical condition. Delusions were the most common (44 [92%]) psychiatric sign and psychosis lasted between 2 and 90 days. A total of 33 (69%) patients required hospitalization to a medical service and 16 (33%) required inpatient psychiatric admission. The majority (26 [54%]) of cases did not assess for delirium and 15 (31%) cases were judged to be of high risk of bias.

Conclusions: Despite the growing awareness of COVID-19’s association with incident psychosis at a population level, cases of COVID-19-associated psychosis often lacked clinically relevant details and delirium was frequently not excluded.

PROSPERO registration number: CRD42021256746.

1. Introduction

Acute and persistent neuropsychiatric sequelae associated with COVID-19, the clinical disease resulting from SARS-CoV-2 infection, are common \cite{1,2}. Although rare, cases of putative COVID-19-associated psychosis have received widespread attention in the media \cite{3}. Questions remain concerning the legitimacy of this connection \cite{4}. The protean causes of psychosis \cite{5} and mortality associated with psychotic illness \cite{6,7} warrant elucidating the relationship between COVID-19 and incident psychosis.

Psychosis has been associated with pandemic respiratory viruses for centuries \cite{8}. A rapid review of the literature identified incident cases of psychosis linked to an infection with SARS, MERS, and influenza (H1N1) in 0.9% to 4% of infections \cite{9}. Individual cases of COVID-19 psychosis have been reported since the outset of the COVID-19 pandemic, followed by small retrospective descriptive studies \cite{10} and larger surveillance studies \cite{11}. More recently, a large population level study showed an increased risk of new onset psychosis in patients with COVID-19 infections \cite{1}. Taquet et al. conducted a retrospective cohort study using electronic health record data demonstrating an increase in incident diagnosis of psychotic disorders in the 6 months following SARS-CoV-2 infection compared to influenza infection \cite{1}. However, newly diagnosed psychotic disorders were more common in older patients, patients hospitalized for COVID-19 and those with encephalopathy \cite{1}. Some have hypothesized that, in addition to emergence of a new clinical entity, this association might represent diagnostic confusion between psychotic disorders and delirium, since delirium was likely underreported in this study \cite{12} and since psychotic disorders are often misdiagnosed in cases of delirium \cite{13,14}. New diagnoses of psychosis might also represent emergence of undocumented mental illness, as electronic health records are limited in their ability to capture mental health diagnoses \cite{15} and patients with psychotic disorders are at
increased risk for COVID-19 infection [16].

As others have argued, it is important to distinguish COVID-19 cases with psychiatric symptoms as part of a broader syndrome (e.g., delirium) from a distinct clinical psychological disorder related to infection [4]. Although case reports are limited in their ability to lead to causal claims, well-constructed cases often provide rich details that are absent in larger, population level studies. Systematic reviews of case reports have a role in documenting common presentations, comorbidities, and outcomes in rare diseases and generating hypotheses [17–20]. A recent review described cases of psychosis in persons with COVID-19, but this was narrative in nature and additional cases have been reported since this publication [4].

The primary objective of this descriptive systematic review of case reports is to describe the clinical comorbidities, presentations and outcomes of adults presenting with incident non-delirious psychosis after or during a SARS-CoV-2 infection and to assess the quality of reports.

2. Methods

2.1. Protocol and registration

This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplement 1) [21] and is registered in the PROSPERO online database (PROSPERO Identifier: CRD42021256746).

2.2. Search strategy and information sources

An academic librarian (MVI) developed a search strategy combining terms for COVID-19 and psychosis (Supplement 2) and systematically searched PubMed, PsycINFO, and Embase from inception through September 22, 2021. We also conducted backward and forward reference searches through September 2021.

2.3. Eligibility criteria

We included studies that met the following inclusion criteria: 1) adult patients (18 ≥ years) 2) patients with a history of documented COVID-19 infection 3) patients with incident psychosis (described by authors) after or concurrent with COVID-19 infection 4) articles identified as case reports, case series, letters to the editor, correspondences, and commentaries describing patient presentations and 5) articles written in English or any language with an English abstract to consider suitability for inclusion. We excluded cases of 1) nonadult patients 2) reports where there was no history of COVID-19 or psychosis 3) cases with a history of psychosis prior to infection 4) articles where authors determined psychosis was explained by another etiology entirely (e.g., substances or medications) 6) studies with no case description and 7) abstracts or articles that were not available as full text. We also excluded cases where authors attributed psychosis entirely to delirium, as COVID-19 is a well-established cause of delirium [22] and psychotic symptoms are common in delirium [14].

2.4. Study selection

Using an online systematic review software (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia), two reviewers (CS, EG) independently screened references in two successive stages after removing duplicates. Reviewers initially reviewed titles and abstracts and removed those that did not meet inclusion criteria or were not available but kept abstracts with insufficient information for full-text evaluation. Reviewers then independently evaluated full text articles and excluded those not meeting inclusion criteria or those that were unavailable. The authors resolved disagreement by discussion with a third author (PR). A physician collaborator (RR) fluent in Spanish translated the single non-English (Spanish) article available as a full text.

2.5. Data extraction

Pairs (PR, CS; NH, CS; EG, CS) of authors independently extracted data from articles using a standardized template. Authors extracted 1) patient demographics (i.e., patient age and sex) and study characteristics (i.e., country and year of publication) 2) comorbidities (i.e., medical, psychiatric and substance use history, and recent psychosocial stressor) 3) medical and psychiatric course of illness (i.e., presence and duration of psychiatric and medical signs and symptoms) and 4) clinical interventions (i.e., hospitalization, receipt of oxygen, intensive care admission, ECT, psychotropic and non-psychotropic medications).

2.6. Quality of studies

Case reports are inherently biased. However, standardized tools have been developed to assess their methodological quality in systematic reviews [23]. Therefore, two authors (CS, PR) independently assessed study quality using a standardized tool adapted from Murad et al. [23,24]. Studies were rated as having low, moderate, or high risk of bias. Because delirium is a clinically distinct but important cause of psychotic signs and symptoms, we also extracted whether authors excluded delirium in their reports and, if so, provided clinical reasoning for doing so. However, we did not include the presence or absence of a delirium evaluation in determining level of bias as this is not equally relevant in each case.

2.7. Data analysis

Given the descriptive nature of this review, we used descriptive statistics to report demographics and clinical characteristics, with means and standard deviation for continuous variables and frequencies and percentages for dichotomous variables. We reported duration of symptoms as a range due to inconsistent and approximate reporting of this information across studies.

3. Results

3.1. Study characteristics and patient demographics

A PRISMA flow diagram of selected studies is presented in Fig. 1. A total of 2396 references were identified, 942 duplicates were removed, and 1323 articles were excluded based on title and abstract review. The

![Fig. 1. PRISMA Flow Diagram.](image-url)
remaining 131 articles were reviewed in full and 91 were excluded. Of excluded articles, 19 described no history of COVID-19, 16 reported no psychosis, and 11 identified premorbid psychotic symptoms. Another 11 articles attributed symptoms entirely to delirium, and 9 articles attributed symptoms to an etiology other than COVID-19. Finally, 18 articles did not include individual level data and 7 articles were available as abstracts only. A total of 40 articles met inclusion criteria, comprising 48 individual patients from 17 countries (Table 1) [25–64]. All but a single study [54] were in English and 20 (42%) cases were reported in the United States, where the largest proportion of these cases were documented. Of the 48 patient cases, 29 (60%) were male and the mean (SD) age of patients across studies was 43.9 years (11.8). A total of 7 (15%) patients had a documented history of mental illness, 6 (13%) a history of substance use and 11 (23%) a comorbid medical condition. Comorbidities for mental illness, substance use and medical conditions were not reported in 2 (4%), 12 (25%), and 14 (29%) cases, respectively (Table 2).

3.2. Clinical characteristics of patients with COVID-19-associated psychosis

Details of patients’ clinical presentations are available in Table 1. Documented psychiatric symptoms lasted between approximately 2 and 90 days. The most common reported sign or symptom of psychosis was delusions (44 [92%]), followed by hallucinations (33 [69%]), disorganized behavior (23 [48%]), disorganized speech (12 [25%]), and catatonia (7 [15%]). Auditory hallucinations (29 [60%]) were the most common form of hallucination, followed by visual (11 [23%]) and tactile (2 [4%]) hallucinations. Mania was reported in 8 (17%) cases and depression in 4 (8%) cases (Table 3). A total of 35 (73%) patients presented with COVID-19 related physical symptoms, lasting between approximately 0 and 35 days. Respiratory symptoms were most common (26 [54%]), followed by fever (16 [33%]), neurologic symptoms (14 [29%]), and gastrointestinal symptoms (7 [15%]). Nonpsychiatric symptoms went unreported in 7 (15%) cases. (Table 3).

3.3. Clinical interventions

Of 48 patients, 44 (92%) were hospitalized in some capacity. A total of 33 (69%) patients were hospitalized to a medical/surgical floor (e.g., medicine or neurology), 16 (33%) to a psychiatric facility and 10 (21%) were initially admitted to a medical/floor and transferred to inpatient psychiatry. For medical treatment of COVID-19, 13 (27%) patients received oxygen and 5 (10%) were admitted to the intensive care unit. Nearly all patients in our sample presented with delusions and depression for medical treatment of COVID-19, 13 (27%) considered delirium but did not describe a formal assessment. It is possible that delirium was not considered in many cases because patients had few physical symptoms present. Another 15% of cases reported a recent episode of delirium during the current illness and many patients received delirious medications (steroids [19%], tociluzumab [6%], favipiravir [4%], chloroquine derivatives [29%] and benzodiazepines [60%]), which further confounds the relationship between COVID-19 and subsequent psychosis, although the temporal relationship between these medication receipt and symptom onset was not always clear. A total of 10% of the cases required intensive care admission, where rates of delirium are particularly high [72] and 23% of cases had visual hallucinations, a common marker of delirious psychosis [13]. This descriptive systematic review identified 48 cases of incident psychosis in patients with antecedent or concurrent COVID-19. The mean age of patients in our sample was 43.9 years and medical comorbidities were present 23% of cases. Delusions were present in 92% of patients and psychiatric symptoms lasted for approximately 2 to 90 days, while nonpsychiatric symptoms for approximately 0 to 35 days. A total of 69% of patients required medical hospitalization and 33% required psychiatric hospitalization. Nearly all patients received anti-psychotic medications. Over half of reports did not consider delirium and 31% of cases were judged to be of high risk of bias. To our knowledge this is the first systematic review of COVID-19-associated psychosis cases.

Consistent with a large retrospective cohort study that showed an increased incidence of new onset psychosis in patients with COVID-19 [1], the mean age of our sample (43.9 years) was higher than expected for new onset psychosis in the general population [65]. Although this age distribution is likely skewed given that we included only adults in our sample, few cases of COVID-19-associated psychosis have been documented in the pediatric population based on our search results. This gap might also reflect underlying vulnerability in older populations to developing psychosis while medically ill [66]. Understanding comorbid medical and substance use history in individuals presenting with psychosis is clinically important since such conditions can precipitate and lengthen duration of psychosis [5,67]. Between 13% and 23% of our sample had a comorbid psychiatric, substance use or medical condition, lower than would be expected for individuals with new psychotic illness [68]. However, approximately 25% of cases did not explicitly document details on substance use or medical history.

4. Discussion

Understanding comorbid medical and substance use history in individuals presenting with psychosis is clinically important since such conditions can precipitate and lengthen duration of psychosis [5,67]. Between 13% and 23% of our sample had a comorbid psychiatric, substance use or medical condition, lower than would be expected for individuals with new psychotic illness [68]. However, approximately 25% of cases did not explicitly document details on substance use or medical history.

Nearly all the patients in our sample presented with delusions and the majority presented with hallucinations at similar rates to those reported in an early retrospective descriptive study of 10 patients presenting with COVID-19 and new onset psychosis [10]. Symptoms were often self-limited in our review, consistent with findings from the Spanish influenza pandemic, where psychosis had resolved in most cases at 5-year follow up [69]. The most common nonpsychiatric symptoms in our sample were respiratory in nature, the prevalence of which was similar to those in a large systematic review of patients with COVID-19 (54% vs. 57%) [70]. Although fewer patients were medically asymptomatic in our sample compared to a large population study of patients with SARS-CoV-2 infection (13% vs 33%) [71], 15% of cases did not detail whether patients presented with nonpsychiatric symptoms.

Given the novelty and uncertainty of COVID-19-associated psychosis as a distinct diagnostic entity, we did not narrow our search to cases where authors documented that psychosis was caused only by COVID-19. Indeed, many cases provided only provisional diagnoses. Potential confounders or mediators between our exposure of interest (COVID-19) and outcome (psychosis) were common across studies. Despite excluding cases where authors attributed psychosis entirely to delirium, 77% of reports in our review either did not explicitly rule out delirium or did not describe how delirium was assessed. It is possible that delirium was not considered in many cases because patients had few physical symptoms present. Another 15% of cases reported a recent episode of delirium during the current illness and many patients received delirigenic medications (steroids [19%], tociluzumab [6%], favipiravir [4%], chloroquine derivatives [29%] and benzodiazepines [60%]), which further confounds the relationship between COVID-19 and subsequent psychosis, although the temporal relationship between these medication receipt and symptom onset was not always clear. A total of 10% of the cases required intensive care admission, where rates of delirium are particularly high [72] and 23% of cases had visual hallucinations, a common marker of delirious psychosis [13]. Importantly, delirium commonly presents with signs and symptoms of psychosis [13,14], is common in COVID-19 [22] and might be a contributor to the increased...
| Study reference          | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/limitations |
|-------------------------|------------------|-------------------------|-------------------------------|---------------------|----------------|---------|-----------------------|-------------------------------------------|-----------------------|
| Alba et al., 2021 [25]  | 40, M, ES        | Sudden onset of disorganized behavior and speech with delusions of death, mystical VI in the form of angels and demons, and the thought that he was possessed. | Flu-like symptoms | None | Not reported | “Confirmed SARS-CoV-2”. Labs otherwise reported as normal, but no values provided. CT chest showed mild pulmonary infiltrates in both lungs. | No COVID-19 treatment. Treated for psychosis with aripiprazole 5 mg and diazepam 15 mg. Psychotic symptoms improved after 1 week home psychiatric admission. | Reported Dx: Brief psychosis related to COVID-19 infection | No labs reported |
| Al-Busaidi et al., 2021 [26] | 45, M, OM       | Two weeks after discharge requiring mechanical ventilation for COVID-19, he jumped out of window after being commanded by God. Was noted to be agitated, suspicious and relate AH from of God. | Shortness of breath, cough, fatigue, anorexia and myalgia for 3 days prior to initial admission for COVID-19 requiring ventilation. | None | None | “Tested positive for COVID-19.” CBC, CMP, thyroid studies were reported as “within normal range.” UDS was negative. CT brain and CXR with no abnormalities. | No COVID-19 treatment. Treated for psychosis with aripiprazole 5 mg and dexamethasone 8 mg for 5 days. | Reported Dx: Psychotic disorder due to COVID-19 | Recent mechanical ventilation, treatment with dexamethasone and HCQ |
| Alvarez-Cimeros et al., 2021 [27] | 43, M, MX       | Tachylalia, disorganized ideas, restlessness, delusions of grandeur, emotional lability, and aggression towards his mother presenting 3 days after father diagnosed with COVID-19. | No symptoms | None | None | A history of hetero-aggressive episodes which usually resolved over 48 h. | For psychosis, haloperidol and promethazine PRN, olanzapine 5 mg QHS with resolution of symptoms by 14 days. | Reported Dx: Brief psychotic disorder | History of transient aggressive episodes. |
| Ariza-Varín et al., 2021 [28] | 48, F, CO        | Developed paranoid and self-referential ideas, fluctuating behavior, and inversion of sleep wake cycle 4 days after diagnosis of COVID-19. Presented with paranoid and mystical delusions and AH that she was on a “mission from God.” | History of cough, fever, malaise, and fatigue for 5 days prior to presenting for care | Borderline intellectual functioning | None | + SARS-CoV-2 PCR, K 3.3 mmol/L, AST 54 U/L, ALT 69 U/L, total bilirubin 2.07 mg/dl, indirect bilirubin 1.73 mg/dl, ferritin 595 ng/mL. Normal CRP, ESR, PCT, fibrinogen, CSF viral PCR, Chinese ink stain. Brain MRI and CT chest unremarkable. | No treatment and patient discharged home with family due to isolation protocol in the hospital and planned for outpatient follow up. | Reported Dx: Manic psychosis and COVID-19 | History of transient aggressive episodes. |
| Austgen et al., 2021 [29] | 52, F, US        | Insomnia and anxiety after receiving steroids for “mild COVID-19,” which progressed to paranoia and depression over 1 month requiring hospitalization. Again hospitalized 48 h later for suicidal thoughts. | Mild upper respiratory symptoms | None | HTN, T2DM | + SARS-CoV-2 PCR, MRI brain, EEG, Smith Ab, DNA Ab, SS-A and SS-B, ANA, RF, Anti-TPO, C4, C3, CSF (SARS-CoV-2, JC, West Nile, encephalitis panel) were negative or normal. CSF IgG was mildly elevated (4.15). Elevated ferritin (238 ng/mL), | For COVID-19, ampicillin/sublactam. Respiratory symptoms resolved after 3 days. For psychosis related to suspected viral encephalitis, acyclovir, high dose methylprednisolone for 5 days. Haloperidol and lorazepam for agitation. Significant improvement even after discontinuing antipsychotics. | Reported Dx: Psychosis associated with probable encephalitis associated with SARS-CoV-2 | History of border line intellectual functioning and “thinking with a high level of pervious mysticism.” |

(continued on next page)
Table 1 (continued)

| Study reference | Age, sex, country | Psychiatric presentation | Psychiatric presentation | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/limitations |
|-----------------|-------------------|--------------------------|--------------------------|----------------|---------|-----------------------|---------------------------------|----------------------|
| Baral et al., 2021 [30] | 53, M, US | After 5 weeks of COVID-19, he experienced delusional thoughts that people, including his wife, were plotting to kill him. | Fever, cough and weakness for 2 days | None | None | CRP (1.35 ng/dL), ESR (34 mm/h) and IL-6 (pg/mL). | + SARS-CoV-2 PCR. Normal EKG, CMP, CBC, UDS, HIV, RPR, LDH, D-dimer, TSH, UA, troponin, INR, LFTs, B12, folate. Ferritin 400.9 ng/mL. Normal CXR and CT head. | 10 days. During readmission, olanzapine 10 mg, sertraline 100 mg, ECT and lorazepam. Recovered by day 47. Symptoms improved within 24 h of “coping skills” from consult service and receipt of haloperidol 5 mg. | Social isolation and fear over 5 weeks preceding psychotic symptoms. |
| Caan et al., 2020 [31] | 43, M, US | Two weeks after upper respiratory symptoms and fever, presented with anxiety about possible COVID-19, insomnia, staring, poor self-care and delusions about “the devil” and AH. After admission, holding abnormal posture, hovering feet above bed and held arms in decorticate posture. | Headache, fever, shortness of breath, cough, weakness, and back pain | None | None | + SARS-CoV-2 PCR. Tachycardic and hypertensive. ALT 281 U/L, AST 79 U/L, INR 1.5. Normal hemoglobin, WBC, TFTs, serum drug screen, lactic acid, PCT, glucose. CXR and CT head normal. LP with negative gram stain; 2 red cells/uL, 1 white cell/uL, protein of 23 mg/dL and glucose of 69 mg/dL. | For COVID-19, azithromycin, albuterol, benzotenate for cough and methocarbamol for pain. For catatonia, lorazepam 1 mg QID and then tapering to 1 mg with good clinical response with only residual psychomotor retardation. | Authors suspected delirium likely impacted catatonic presentation. |
| Chacko et al., 2020 [32] | 52, M, US | One week of decreased speech, delusions that he caused the COVID-19 pandemic. | None | None | OSA | -SARS-CoV-2 PCR, +IgG. Elevated LFTs (no values provided), ESR 40 mm/h, CRP 1.5 mg/l, D-dimer 1003 μg/mL. UA reported to be consistent with dehydration. CT chest consistent with multifocal pneumonia. | Ceftriaxone and azithromycin for infection and lorazepam 1 mg BID, fluoxetine 20 mg, olanzapine 5 mg BID, sertraline 100 mg, clonazepam 0.25 mg BID, trazadone 50 mg po QHS and ECT for psychosis. Improved after 6 ECT sessions. | No CSF labs |
| DeLisi, 2021 [33] | 34, M, US | Paranoid delusions that the world would end soon, hyper religiosity and grandiosity that he was on a special mission to help God. Fear led him to consider jumping off a bridge. | Headache | Alcohol misuse | None | “Positive for SARS-CoV-2.” Normal CMP, CK, IgG, IgM, herpes ab, ANA, thyroid hormone. CXR and CT head normal. MRI scan showed a few punctate nonspecific hyperintense foci in the right centrum semiovale. | No COVID-19 treatment. Psychosis treated with risperidone 4 mg. Eventually improved and discharged from psychiatric hospital with risperidone. | Recent significant social stressors (job loss and isolation), and heavy drinking that escalated over 2 months. |
| Desai et al., 2021 [34] | 55, F, US | 3 weeks after a medical admission for COVID-19, presented with pressured speech and AVH of God asking her to save the earth. | Symptoms not reported but had recent admission 3 weeks prior for COVID-19 requiring oxygen, steroids and remdesivir. | None | HTN, T2DM, Obesity | Reported COVID-19 3 weeks prior. - SARS-CoV-2 PCR on admission. HR. 130 bpm. BP 147/119. LDH 825 units/L, WBC 4500 cells/mm3. “Infectious disease work-up negative.” MRI and CT brain unremarkable. UDS negative. | For COVID-19, steroids, oxygen and remdesivir weaned off before admission to psychiatry. For psychosis, haloperidol, diphenhydramine and lorazepam for agitation | Recent treatment with steroids and remdesivir |

(continued on next page)
| Study reference          | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies                                                                 | Treatment and Outcome                                                                                      | Reported and approximated DSM-5 Diagnosis                                                                 | Confounders/limitations |
|-------------------------|-------------------|--------------------------|-------------------------------|--------------------|----------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------**********************************************|
| Ellil et al., 2021 [35] | 20, F, US         | Insomnia and panic attacks progressed over a 2-weeks, leading to disorganized thoughts, paranoia, flight of ideas, forgetfulness, and VH of her recently decreased grandmother. | Fatigue            | None              | Mild intermittent asthma and atopic dermatitis | + SARS-CoV-2 PCR, Elevated UDS, BAC, CSF, heavy metals, meningitis panel, HEV, tracheome pulldatum, CBC, ESR, CRP, CK, TSH, folic acid, B12, CSF, AIE panel. EEG, CT/MRI head normal. | Followed by aripiprazole 10 mg daily and valproate 1000 mg daily with improved symptoms by 14 days. Quetiapine and high dose lorazepam. Discharged home on lorazepam taper for catatonia. | Reported Dx: COVID-19-induced psychotic disorder | Labs for infectious evaluation not reported. SARS-CoV-2 infection was 2 weeks prior. |
| Faisal et al., 2021 [36] | 48, M, ID | Anxiety with AVH, followed by depression during confinement. | Dyspnea and dry cough on day of admission with fever 5 days prior. Nausea, vomiting and diarrhea 10 days prior to admission. | None | None | + SARS-CoV-2 PCR, Elevated D-dimer (2360 mg/L), fibrinogen (408 mg/dL), CRP (30 mg/L), ferritin and LFTs (ALT 106 U/L, AST 56 U/L), lymphopenia (17%). CT brain normal, CXR with multifocal ground glass opacity. | For COVID-19, oseltamivir, HCQ, azithromycin and vitamin C. For psychosis, haloperidol on day 1 and 2 as needed and risperidone and lorazepam. Symptoms resolved by day 13. | Reported Dx: Brief psychotic disorder due to COVID-19. | Received HCQ, but after symptoms started. |
| Ferrando et al., 2020 [37] | 30, M, US | Bizarre behavior, anxiety, suicidal ideation, agitation AH of people who were chasing him, decreased sleep, and potomania. | None | None | Not reported | “Positive for COVID-19.” CRP 0.67 mg/dL, ferritin 421 µg/L, CBC, CMP normal. CT head, CXR normal. | Improved after 4 days of quetiapine 25 mg. | Reported Dx: Psychosis associated with COVID-19 | Limited history available. |
| Ferrando et al., 2020 [37] | 34, F, US | Inattention, pressured speech, disorganization, and agitation. Focused on “fire burning up inside” and migratory numbness and tingling. | None | Panic disorder | Not reported | “COVID-19-positive.” WBC 2.8 k/mm³, CRP 1.89 mg/dL, ferritin, and CMP normal. CT head, CXR normal. | Lorazepam, aripiprazole, and clonazepam for psychosis. HCQ and azithromycin for COVID-19. Improved after admission. | Reported Dx: Psychosis associated with COVID-19 | History of panic disorder diagnosis. |
| Ferrando et al., 2020 [37] | 33, M, US | Persecutory delusions and AH of ex-wife and others outside trying to kill him for 4 days. | None | Opioid use disorder | Not reported | “COVID-19 positive.” CRP 1.9 mg/dL, ferritin, D-dimer, CBC and CMP reported as normal. CT head and CXR normal. | Quetiapine for psychosis. Transferred out of psychiatric unit. | Reported Dx: Psychosis associated with COVID-19 | On Methadone for OUD. |
| Gillet et al., 2020 [38] | 37, M, UK | Insomnia, concern about infecting his family, preoccupation with biblical passages, and reports of seeing the devil. Five-day history of fever, cough, SOB myalgia, and severe insomnia. | None | None | Not reported | + SARS-CoV-2 PCR. Leukocytosis with lymphopenia. Normal CRP, BMP, UDS, CSF/serum autoimmune markers normal. | Prolonged ICU admission for surgical wounds with difficulty weaning from sedation for COVID-19. Olanzapine and diazepam for Delirium vs. single acute psychotic episode vs. manic episode | Reported Dx: Psychotic disorder due to COVID-19, with hallucinations | Occupation as a healthcare worker may have contributed to his presentation. |

(continued on next page)
### Table 1 (continued)

| Study reference | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/limitations |
|-----------------|-------------------|--------------------------|-------------------------------|---------------------|----------------|---------|----------------------|------------------------------------------|-----------------------|
| Haddad, et al., 2020 [39] | 30, M, QA | Developed anxiety after positive COVID-19 test, followed by paranoid delusions and AH 1 week later. | Mild symptoms of COVID-19 were anosmia and ageusia | Anxiety | None | +SARS-CoV-2 PCR. Normal CBC/CMP. Ferritin 623 μg/L, CRP normal (<5 mg/L). CRP 12.3 mg/L prior to illness. CXR, CT brain normal | Azithromycin, ceftriaxone and HCQ. Lorazepam 1 mg QID, mirtazapine 30 mg QHS, risperidone 1 mg BID x 4 weeks. | DSM-5 Dx: Delirium due to COVID-19 acute, hyperactive vs. Psychotic disorder due to COVID-19, with hallucinations | Family history of psychotic episodes. Possible concomitant delirium. Received HCQ early in his course. |
| Huarcaya-Victoria, et al., 2020 [40] | 23, F, PE | After COVID-19 diagnosis presented with insomnia, incoherent speech, reports of hearing voices calling her and religious delusions. | None | Fever | Not reported | “Positive IgM/IgG antibodies against COVID-19.” Normal CBC | For psychosis, IV midazolam, ziprasidone 40 mg, olanzapine 15 mg. For COVID-19, none reported. | DSM-5 Dx: Brief psychotic disorder, with marked stressor | History of affective disorder. Limited details provided. |
| Huarcaya-Victoria, et al., 2020 [40] | 38, F, PE | Presented with 2 weeks of insomnia, 1 week of increased speech quantity and 3 days of mystical religious delusions. | None | Depression | Not reported | “Positive IgM/IgG antibodies against COVID-19.” Normal CBC, CRP 6 mg/L | Ziprasidone 20 mg, olanzapine 20 mg, VPA 1000 mg/day, 1 mg/day clonazepam for psychosis. No treatment for COVID-19 reported. Discharge after 10 days with remission of psychotic symptoms. | DSM-5 Dx: Brief psychotic disorder, without marked stressor | Limited details provided. |
| Huarcaya-Victoria, et al., 2020 [40] | 47, F, PE | Presented with 4 months of grief following mother’s death and 3 weeks of command AH, delusions, and suicide attempts. | None | Not reported | Not reported | “Positive IgM/IgG antibodies against COVID-19”. WBC 5.1, Hgb 13.9 g/dL, Pt 384 × 10^9/L, CRP 1.5 mg/L. | Haloperidol 15 mg, quetiapine 300 mg/day, 50 mg/day sertraline, VPA 500 mg/day for psychosis. No treatment for COVID-19 reported. Discharged from hospital after 10 days with remission of psychotic symptoms. | Reported Dx: Acute psychotic disorder | Recent death of mother with antecedent depressed mood. |
| Jaworowski et al., 2020 [41] | Not reported, M, IL | Acutely psychotic with grandiose and religious delusions. | Mild respiratory symptoms | None | Not reported | “Tested positive for COVID-19.” No other labs reported. IM haloperidol and lorazepam for psychosis. None reported for COVID-19. Recovery of psychosis over 2 days. | DSM-5 Dx: Brief psychotic disorder | Limited case details. | Limited case details. | (continued on next page) |
| Study reference | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/limitations |
|-----------------|------------------|-------------------------|-------------------------------|-------------------|---------------|---------|-----------------------|--------------------------------------------|------------------------|
| Jaworowski et al., 2020 [41] | 25, M, IR | Irritable mood, claiming to communicate with God, laughing to himself, walking down the street naked. | Respiratory symptoms | Not reported | Not reported | “COVID disease.” CT chest with “possible COVID-19.” Normal CT brain after ECT. | Psychotic and mood symptoms improved after 6 session ECT. | DSM-5 Dx: Bipolar I disorder, current episode manic, severe, with mood congruent psychotic features | Limited case details. |
| Jaworowski et al., 2020 [41] | 49, F, US | Admitted to psychiatry with 2 weeks of thoughts of jumping in front of a train, weight loss, agitation, guilt about her grandmother’s death 40 years ago and “paranoid delusions.” | 3-week history of intermittent cough and anorexia. | None | None | “Tested positive for SARS-CoV-2.” CBC, glucose, BMP, LFTs, TFTs normal. UA with moderate leukocytes, + ketones. Urine microscopy with few bacteria, 25–50 white cells, 5–10 red cells. UDS, lithium, carbamazepine, and valproic acid levels were negative. CSF, EEG and CT head unremarkable. | For COVID-19, azithromycin PO and hydroxychloroquine PO for 5 days. | DSM-5 Dx: Psychotic disorder due to COVID-19, with delusions | Recently stopped working and had a breakup with her partner 2 months before admission. |
| Kazi et al., 2021 [43] | 56, F, US | Hallucinations and bizarre delusions ‘talking about numbers on the wall’ prior to admission. While admitted, had AVH that God was speaking with her, and “inflated self-esteem.” | None | T2DM (A1c 14.4), HTN | Presented with 2 weeks of dyspnea, chills and cough in the setting of positive SARS-CoV-2 test, requiring admission for acute hypoxic respiratory failure. | “Tested positive for SARS-CoV-2 infection.” Hyponxia. CRP, ESR, D-Dimer “elevated.” A1c 14.4. UDS, RPR, HIV negative. QTC 550 ms. CXR with consolidation. CT angiogram of chest with pulmonary infiltrates. CT head normal. | Received high flow O2, vitamin C, vitamin D, zinc, monoclonal antibody, tocilizumab, dexamethasone (10 days), remdesivir (5 days). | DSM-5 Dx: Psychotic disorder due to COVID-19, with hallucinations | Received multiple deliriogenic medications. |
| Study reference   | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/limitations |
|------------------|------------------|--------------------------|-------------------------------|---------------------|----------------|---------|----------------------|--------------------------------------------|------------------------|
| Khatib et al., 2021 [44] | 50, M, UK | After discharge from COVID admission on oral steroids, developed anxiety, insomnia, tactile visual and auditory hallucinations, and eventually developed head banging and physical agitation. | Patient was admitted with hypoxia and breathlessness requiring ICU admission. | None | T2DM, NAFLD, HTN | +SARS-CoV-2 PCR. Normal CRP, and WBC. CXR with bilateral patchy consolidations, CT with fibrosis and organizing pneumonia. MRI brain normal. | Dexamethasone, remdesivir, tocilizumab, amoxicillin, clarithromycin, and Piperacillin-Tazobactam for COVID-19. Risperidone for psychosis. | Occurred in the setting of steroids and after ICU admission. |
| Lim et al., 2020 [46] | 58, M, US | Confusion, aggressive behavior, disorganized speech, and hallucinations. | Cough, body aches, chills, nausea, and vomiting. | Panic disorder, alcohol, and cocaine use | CAD, HCV, liver disease | +SARS-CoV-2 PCR. ALT 114 U/L, AST 126 U/L, ammonia 40 μmol/L, WBC 2.4, UDS/BAC neg. CRP 6.5 mg/L, ferritin 110 ng/mL, CK 723 IU/L. CT brain with no acute intracranial processes. Liver US with ascites. “Nasopharyngeal swab positive for COVID-19.” CRP 121.2 mg/L, D-dimer 1200 μg/L, fibrinogen 7.28 g/L, ferritin 1291 μg/L, TNF alpha 6.47 pg/mL. paraneoplastic Ab negative, HIV, syphilis, TSH, B12 wnl. CSF <1 WBC, protein 0.18 g/L. CT chest with bilateral ground-glass opacities, MRI brain and. EEG normal. | Haloperidol and lorazepam for psychosis. HCQ and supportive care for COVID-19. Symptoms resolved with antipsychotic and benzodiazepine. Lorazepam, haloperidol, and risperidone for psychosis. Treated symptomatically with fluids and oxygen for COVID-19. Discharged after 20-day psychiatric hospitalization with full remission of psychiatric symptoms by day 52. | Antecedent hepatic encephalopathy, severe sepsis. |
| Lim et al., 2020 [46] | 55, F, UK | Readmitted 2 days after medical discharge with new onset delusions, hallucinations, agitation, and disorientation. | Fever, myalgia, cough, dyspnea, loss of taste/smell and headache. | None | History of renal calculi | +SARS-CoV-2 PCR. ALT 114 U/L, AST 126 U/L, ammonia 40 μmol/L, WBC 2.4, UDS/BAC neg. CRP 6.5 mg/L, ferritin 110 ng/mL, CK 723 IU/L. CT brain with no acute intracranial processes. Liver US with ascites. “Nasopharyngeal swab positive for COVID-19.” CRP 121.2 mg/L, D-dimer 1200 μg/L, fibrinogen 7.28 g/L, ferritin 1291 μg/L, TNF alpha 6.47 pg/mL. paraneoplastic Ab negative, HIV, syphilis, TSH, B12 wnl. CSF <1 WBC, protein 0.18 g/L. CT chest with bilateral ground-glass opacities, MRI brain and. EEG normal. | Haloperidol and lorazepam for psychosis. HCQ and supportive care for COVID-19. Symptoms resolved with antipsychotic and benzodiazepine. Lorazepam, haloperidol, and risperidone for psychosis. Treated symptomatically with fluids and oxygen for COVID-19. Discharged after 20-day psychiatric hospitalization with full remission of psychiatric symptoms by day 52. | Recent episode of delirium. |

(continued on next page)
| Study reference        | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/ limitations |
|------------------------|-------------------|--------------------------|-------------------------------|--------------------|----------------|---------|----------------------|-------------------------------------------|--------------------------|
| Lorenzo-Villalba et al., 2020 [49] | 33, F, FR         | Presented with 1 day of AIL, disrupted sleep and disorganized speech, after being found nude in a building basement. | None                          | None               | None           | WBC $22.3 \times 10^7$ cells/μL, CRP 98 mg/L, ABG with pO2 72 mmHg. Urine/serum tox negative. CT brain normal. CT chest with ground-glass opacities. | Olanzapine 10 mg daily for psychosis. Treated with supplemental oxygen for 7 days for COVID-19. Oxygen requirement resolved by day 7 and psychosis resolved by day 14. | Limited case details. |
| Majadas et al., 2020 [50] | 63, M, ES         | Persistent delirium after COVID-19 admission and was readmitted with delusions and AIL. | Respiratory symptoms          | None               | None           | +SARS-CoV-2 PCR. Elevated D dimer. CT angiography showed a low-risk pulmonary embolism. MRI brain normal. | COVID-19 was treated with lopinavir-ritonavir, tocilizumab, HCQ, and 3 days of steroids. Psychosis treated with risperidone to 6 mg daily. Psychotic symptoms resolved during hospitalization. Risperidone, lorazepam, valproic acid and quetiapine for psychosis. Enoxaparin and edoxaban for pulmonary embolism and ceftriaxone for COVID-19. Improvement in psychotic symptoms by 1 month outpatient follow up. | Recent episode of delirium |
| Makivic, 2021 [51]     | 46, M, AT         | On day 21 of symptoms, patient developed hallucinations and discharged on risperidone, then readmitted a few hours later with suspected psychogenic seizures. | Cough hemoptysis, headache, dysgeusia, vomiting and diarrhea on home quarantine. | None               | obesity         | +SARS-CoV-2 PCR. D dimer 17 mg/L, LDH 267 u/L, elevated CRP. CT angiography with pulmonary embolism. MRI and CT brain normal. | For psychosis, initially treated with haloperidol and then lorazepam. Treated with IVIG 2 g/kg over 3 days on day 35. For COVID-19, received supportive treatment. He had improvement in cognitive and psychotic symptoms on day 1 after IVIG and was discharged without antipsychotics. | Concurrent massive pulmonary embolism. |
| McAlpine et al., 2021 [52] | 30, M, US         | Developed erratic sleep, disorganized speech, and religious delusions, eventually presenting to emergency department on day 22 for aggression and discharged with haloperidol, only to represent on day 34 with anxiety and aggression. | Fever and malaise              | None               | None           | +SARS-CoV-2 PCR. UDS negative. SF with no WBC, protein 41.2 mg/dL, no oligoclonal bands, but elevated SF IgG 4.8 mg/dL. AIE panel negative. Ferritin 1124 ng/mL, D dimer 1.90 mg/L, TSH 2.52 uIU/mL, CRP 17.7 mg/L. CT and MRI brain unremarkable. 12-h EEG normal. | For psychosis, initially treated with haloperidol and then lorazepam. Treated with IVIG 2 g/kg over 3 days on day 35. For COVID-19, received supportive treatment. He had improvement in cognitive and psychotic symptoms on day 1 after IVIG and was discharged without antipsychotics. | Presence of novel neuronal antibody. |
| Mirza et al., 2020 [53] | 53, M, US         | Suicide attempt by drinking bleach, responding to internal stimuli, auditory hallucinations telling him to harm himself. | Tachycardia, fever, riger, and hypoxic respiratory failure due to pneumonia. | None               | None           | +SARS-CoV-2 PCR. Elevated BUN and transaminases but not reported. CT scan head within normal limits. | Olanzapine 5 mg intramuscular x3 over course of stay for psychosis. Ceftriaxone, azithromycin, HCQ and supplemental oxygen for COVID-19. Back to baseline by discharge | Possible subacute delirium responsible for symptoms. |
|                        | 43, M, ES         | Not reported | None | None | + SARS-CoV-2 PCR. Hemoglobin, renal function, | Olanzapine 10 mg for 2 weeks for psychosis. COVID-19 | Lab values not reported. | Isolation due to quarantine. | (continued on next page) |
| Study reference | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/limitations |
|-----------------|------------------|--------------------------|-------------------------------|--------------------|----------------|----------------|----------------------|------------------------------------------|-------------------------|
| Mollà Roig et al., 2021 [54] | | Paranoid delusions of being spied on at home through his WiFi. | | | | | | | | |
| Noone et al., 2020 [55] | 49, M, US | One week of insomnia and odd statements, oriented only to year, hallucinations, grandiose delusions, passive suicidal ideation and affective lability. | | | | | | | | |
| Noone et al., 2020 [55] | 34, F, US | Bizarre behavior (disrobing in front of strangers), insomnia, persecutory delusions about landlord and belief she was being watched. | | | | | | | | |
| Panarielloa et al., 2020 [56] | 23, M, IT | Hospitalized after 3 days of psychotic symptoms, including thought disinorganization, persecutory delusions and command auditory hallucinations, | | | | | | | | |
| Parker et al., 2021 [57] | 57, M, US | Psychomotor agitation, acute fearfulness, nonsensical thought process with loose associations, response to internal stimuli with paranoid delusions that wife poisoning him. | | | | | | | | |

(continued on next page)
| Study reference | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/limitations |
|-----------------|------------------|--------------------------|-------------------------------|---------------------|-----------------|---------|----------------------|------------------------------------------|------------------------|
| Santos et al., 2021 [59] | 61, M, PT | Convincing his spouse was being unfaithful and that she was having “erotic” conversations with unknown persons on audio recordings on his phone. Noted to have “functional” AH on exam. Symptoms began 2 days before myalgia, fever, and COVID-19 diagnosis, but presented to ED 30 days later. | 1 week of cough myalgia and fever due to COVID-19 | None | Not reported | with elevated glucose and toxicplasmosis IgG, but negative IgM. MRI of the brain with only mild cerebral volume loss. Unremarkable EEG. | + SARS-CoV-2 PCR, CBC, “Biochemical profile,” UA, “serologic tests,” TFTs, “drug tests,” and “vitamin levels” were unremarkable. Head CT was normal. | paranoid delusions an AH did not improve, so switched to risperidone and transferred to psychiatry after admitted to neurology and improved with no psychosis on follow up. No treatment mentioned for COVID-19 and cough, myalgia resolved after 1 week. | Reported Dx: Organic delusional disorder due to COVID-19 | Limited case details. No lumbar puncture. |
| Sen et al., 2021 [59] | 33, F, TR | Paranoid delusions that children were under effects of bad spirits and that husband having an affair. Also with insomnia, irritability, anxiety, dysphoric and manic | None | None | None | + SARS-CoV-2 IgM. WBC 9.6 × 10^3 cells/μL, CRP 123 mg/dL, fibrinogen 625 mg/dL, ferritin 214 microg/L, D-Dimer 1.25 mg/mL, all else wnl. MRI brain showed hypointense signal in splenium of corpus callosum, resolved on day 5. | For psychosis, risperidone 2 mg daily and lorazepam 0.5 mg daily. Transitioned to haloperidol 20 mg daily and biperiden 10 mg daily. Discharged 24 h after near resolution of symptoms and did not return at 3 month follow up on 1 mg risperidone. Discharged day 14 on olanzapine 20 mg daily. For psychosis, received haloperidol 20 mg daily and biperiden 10 mg daily. Discharged after 15 days with resolution of symptoms and did not return at 3 month follow up on 1 mg risperidone. | Reported Dx: SARS-CoV-2-associated first episode of acute mania with psychotic features | No CSF studies |
| Smith et al., 2020 [60] | 36, F, US | Paranoid delusions that she was being tracked by cell phone and that someone was attempting to steal her stimulus check. Attempted to pass children through a drive through window. | Rhinorrhea and nasal congestion | None | Erythema multiforme | + SARS-CoV-2 PCR. WBC 11.5 × 10^3 cells/μL, CRP 2.37 mg/dL, D-dimer 2274 ng/mL, normal electrolytes, ferritin, renal function, urine analysis, UDS and CSF. MRI brain within normal limits | Olanzapine 2.5 mg and 5 mg which was transitioned to risperidone 3 mg daily and clonazepam. Supportive treatment for COVID-19. Near resolution of symptoms despite discontinuation of medication 1 week post-discharge | Reported Dx: Brief psychotic disorder associated with COVID-19 | Recent domestic dispute with psychosocial distress. |
| Tuna et al., 2021 [61] | 52, F, TR | Admitted after trying to jump out wind of house, with AH telling her to kill herself | Not reported | None | None | + SARS-CoV-2 PCR. Low dose CT chest consistent with COVID-19 pneumonia. “Neuroimaging” did not have pathology. | Hydroxychloroquine x 5 days for COVID-19 and haloperidol 10 mg for psychosis. Improvement in symptoms after 1 week. | Reported Dx: Schizophreniform disorder | Limited case details. Symptoms began 1 month ago and unclear when infected with SARS-CoV-2 |
| Vepa et al., 2020 [62] | 40, M, UK | Hallucinations of staff constantly talking about him, paranoid delusions that staff were against | Six days of cough, dyspnea and nasal congestion with prodrome of fever, | None | None | + SARS-CoV-2 PCR. WBC 12 × 10^3 cells/μL, ANC 10.3, CRP 19 mg/dL, 0 WBC in CSF. CT chest consistent with COVID-19 pneumonia. “Neuroimaging” did not have pathology. | Haloperidol and eventually intubation for psychosis. Improved after 24 h of | Reported Dx: COVID-19 induced acute psychosis | Did not consider delirium despite mention of acute confusion. | (continued on next page)
| Study reference | Age, sex, country | Psychiatric presentation | Non-psychiatric presentation | Psychiatric history | Medical history | Studies | Treatment and Outcome | Reported and approximated DSM-5 Diagnosis | Confounders/limitations |
|-----------------|-------------------|--------------------------|-------------------------------|--------------------|----------------|---------|----------------------|------------------------------------------|-------------------------|
| Yesilkaya et al., 2021 [63] | 41, F, TR | Paranoid thoughts of “viral occupation of body” with suicidal ideation 2 months after treatment for COVID-19 | Anosmia, myalgia, and sore throat | None | None | + SARS-CoV-2 PCR. Only reported “blood tests indicated no systemic inflammation” | Olanzapine 20 mg daily and then ECT 8 sessions for psychosis. Favipravir and HCQ for COVID-19. | Limited case details. |
| Zain et al., 2021 [64] | 69, F, US | Bizarre behavior, paranoid delusions, VH and loose associations with catatonic signs of agitation, rigidity, and echolalia | Cold like symptoms with severe cough 2 months prior to presentation | None | COPD, HTN, T2DM | + SARS-CoV-2 IgG. AST 68 ALT 38, UDS negative, Cr 0.4, total CK 628 U/L, Troponin I 0.147 mg/dL, WBC 6.1 × 10^9 cells/μL, CRP <0.9 mg/dL. TTE normal. | Psychosis treated with haloperidol 2 mg daily, followed by lorazepam 0.5 mg TID, clonazepam 1 mg BD at discharge. | Negative SARS-CoV-2 PCR |

Table abbreviations: Ab, Antibody; ABG, Arterial blood gas; ANA, Antinuclear antibody; AH, auditory hallucinations; AIE, Autoimmune encephalitis; ANC, Absolute neutrophil count; ALT, Alanine transaminase; AST, Aspartate aminotransferase; AT, Austria; AVH, Auditory visual hallucinations; BAC, Blood alcohol concentration; BID, twice daily; BMP, Basic metabolic panel; BUN, Blood urea nitrogen; CBC, Complete blood count; CK, Creatine kinase; CMP, Complete metabolic panel; COPD, Chronic Obstructive Pulmonary Disease; COVID-19, Coronavirus Disease 2019; CRP, C-reactive protein; CSF, Cerebrospinal fluid; CT, Computer tomography; CXR, Chest radiograph; DSM-5, Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition; Dx, Diagnosis; ECT, Electroconvulsive therapy; EGG, Electroencephalogram; EKG, Electrocardiogram; ES, Spain; ESR, Erythrocyte sedimentation rate; FR, France; Hgb, hemoglobin; HBV, Hepatitis B Virus; HCQ, Hydroxychloroquine; HCV, Hepatitis C Virus; HIV, Human Immunodeficiency virus; HTN, Hypertension; ICU, intensive care unit; ID, Indonesia; Ig, Immunoglobulin; IL, Israel; IN, India; INR, International normalized ratio; IR, Iran; IT, Italy; K, Potassium; LDH, Lactate dehydrogenase; LFT, Liver function test; MA, Morocco; MRI, Magnetic resonance imaging; MX, Mexico; NAFLD, Nonalcoholic fatty liver disease; OSA, Obstructive sleep apnea; OUD, Opioid use disorder; PCR, Polymerase chain reaction; PCT, Procalcitonin; PE, Peru; Plt, Platelet; QA, Qatar; QHS, nightly; QID, Four times daily; RPR, Rapid Plasma Reagin; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; SOB, Shortness of breath; T2DM, Type 2 diabetes; TNF, Tumor necrosis factor; TR, Turkey; TSH, Thyroid stimulating hormone; TTE, Transesophageal echocardiogram; UDS, Urine drug screen; UK, United Kingdom; UA, Urinalysis; US, Ultrasound; VDRL, Venereal disease research laboratory test; USA, United States of America; VPA, Valproic acid; VH, Visual hallucinations; WBC, White blood cells.
incidence of psychotic disorder diagnoses in patients with COVID-19 [12]. Indeed, we excluded 11 reports of psychosis due to COVID-19 delirium in our review. Unlike a previous narrative review [4], which included cases of psychosis in individuals without COVID-19 [73], we included only those with a reported infection. However, 31% of patients also had a recent psychosocial stressor, which are known to precipitate psychosis in vulnerable individuals [74,75].

In this review, there were a few examples of low bias cases that convincingly excluded delirium. There were also two cases of psychosis attributed autoimmune encephalitis which improved with steroids [28,52], one of which identified a novel autoantibody [52]. So, although COVID-19-associated psychosis could represent a distinct clinical entity, we suggest that non-delirious psychosis in COVID-19 is less common than has been reported in epidemiologic studies [1], consistent with previous commentary on the subject [12].

The numerous confounders between SARS-CoV-2 and incident psychosis highlighted by this review should give clinicians pause when attributing psychosis to COVID-19 without a detailed clinical assessment. Clinical evaluation should include a thorough review of medical, psychiatric and substance use history along with a detailed clinical assessment for delirium using a validated screening tool [76], something that was commonly missing from evaluations in this review. Clinicians should also clearly assert whether they suspect psychotic signs and symptoms are related to delirium. If delirium is present, psychiatrists should work with medical specialists to identify the underlying etiology and treat accordingly. Based on the American Psychiatric Association practice guidelines for schizophrenia [77], neuroimaging and lumbar puncture should be considered in the presence of focal neurological deficits, new onset seizures, later age onset, or concern for autoimmune encephalitis (e.g., personality change, rapid onset of deficits over 3 months or less, lethargy or decreased level of consciousness). Given reported cases of autoimmune encephalitis in COVID-19-associated psychosis [28,52], the threshold for obtaining these studies in cases of psychosis associated with COVID-19 that have excluded delirium should be low.

There are several limitations of this retrospective review. First, case reports are inherently anecdotal, provide a non-random sample, and do not allow for claims of causality in many cases [78]. Given our clinical expertise is limited to adult medicine and psychiatry and the small number of COVID-19-associated psychosis cases in the pediatric population, the scope of the review was limited to adults. The review was based on non-systematic reporting of clinical information and many cases lacked relevant clinical details or were of low quality. We conducted a comprehensive search, including citation analysis, however, there were some studies for which only an abstract was available. Finally, we did not include patients from retrospective descriptive studies that aggregated data and excluded individual case details [10,11,79]. Despite these limitations, the strength of this study is the use of a systematic approach and standardized assessment of quality in cases of COVID-19-associated psychosis.

5. Conclusions

Psychosis is a complex condition with many etiologies, and there have been an increasing number of case reports describing psychosis in

---

**Table 2**

Characteristics of patients with COVID-19-associated psychosis cases.

| Variable          | n (n (%))     |
|-------------------|---------------|
| Age (Mean [SD])   | 43.9 (11.8)   |
| Sex: n (%)        |               |
| Male              | 29 (60%)      |
| Country: n (%)    |               |
| Austria           | 1 (2%)        |
| Colombia          | 1 (2%)        |
| France            | 1 (2%)        |
| India             | 1 (2%)        |
| Indonesia         | 1 (2%)        |
| Iran              | 1 (2%)        |
| Israel            | 3 (6%)        |
| Italy             | 1 (2%)        |
| Mexico            | 1 (2%)        |
| Oman              | 1 (2%)        |
| Peru              | 3 (6%)        |
| Portugal          | 1 (2%)        |
| Qatar             | 2 (4%)        |
| Spain             | 3 (6%)        |
| Tukey             | 3 (6%)        |
| United Kingdom    | 4 (8%)        |
| United States     | 20 (42%)      |
| Comorbidity: n (%)|               |
| Mental health     | 7 (15%)       |
| Not reported      | 2 (4%)        |
| Substance use     | 6 (13%)       |
| Not reported      | 12 (25%)      |
| Medical           | 11 (23%)      |
| Not reported      | 14 (29%)      |

N = 48, except for age (n = 45).

---

**Table 3**

Clinical presentation and interventions for patients with COVID-19-associated psychosis (n = 48).

| Clinical presentation          | n (%)     |
|-------------------------------|-----------|
| Delusions                     | 44 (92%)  |
| Hallucinations                | 33 (69%)  |
| Auditory hallucinations       | 29 (60%)  |
| Visual hallucinations         | 11 (23%)  |
| Tactile hallucinations        | 2 (4%)    |
| Disorganized behavior         | 23 (48%)  |
| (other than catatonia)        |           |
| Catatonia                     | 7 (15%)   |
| Disorganized speech           | 12 (25%)  |
| Mania                         | 8 (17%)   |
| Depression                    | 4 (8%)    |
| Days of psychiatric symptoms  | 2–90      |
| Not reported                  | 6 (13%)   |
| Nonpsychiatric presentation   |           |
| Asymptomatic                  | 6 (13%)   |
| Symptomatic                   | 35 (73%)  |
| Fever                         | 16 (33%)  |
| Respiratory                   | 26 (54%)  |
| Neurologic                    | 14 (29%)  |
| Gastrointestinal              | 7 (15%)   |
| Not reported                  | 7 (15%)   |
| Days of nonpsychiatric symptoms | 0–35   |
| Not reported                  | 22 (46%)  |

| Clinical Interventions        | n (%)     |
|-------------------------------|-----------|
| Variable                      |           |
| Hospitalization               | 44 (92%)  |
| Medical                       | 33 (69%)  |
| Psychiatric                    | 16 (33%)  |
| Medical and Psychiatric       | 10 (21%)  |
| ICU                           | 5 (10%)   |
| Service not reported          | 5 (10%)   |
| Oxygen requirement            | 13 (27%)  |
| Nonpsychotropic medication    |           |
| Steroids                      | 9 (19%)   |
| Tocilizumab                   | 3 (6%)    |
| Favipiravir                   | 2 (4%)    |
| Remdesivir                    | 3 (6%)    |
| Chloroquine derivative        | 14 (29%)  |
| Psychotropic medication       |           |
| Antipsychotic                 | 46 (96%)  |
| Benzodiazepine                | 29 (60%)  |
| Antidepressant                | 6 (13%)   |
| Mood stabilizer               | 6 (13%)   |
| ECT                           | 4 (8%)    |
patients with COVID-19. The findings of this descriptive systematic review suggest that the clinical presentations and case descriptions often lacked clinically relevant details, including how or if delirium was excluded in patients with COVID-19-associated psychosis. Reports of non-delirious psychosis related to COVID-19 might therefore be over-reported. Prospective studies are warranted to further clarify the relationship between COVID-19 and incident psychosis.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of Duke University, the U.S. Government or any of its agencies.

Funding/Support

Not applicable.

Declaration of competing interest

None reported.

Acknowledgements

The authors appreciate the assistance of Robert Rolfe, MD for language services during the review process.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.genhosppsych.2020.10.003.

References

[1] Taquet M, Geddes JR, Hinson M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021 May;8(5):416–27. https://doi.org/10.1016/S2215-0366(21)00084-5. Epub 2021 Apr 6. PMID: 33836148; PMCID: PMC8023694.

[2] Rogers JP, Chenney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020 Jul;7(7):611–27. https://doi.org/10.1016/S2215-0366(20)30203-6. Epub 2020 May 18. PMID: 32437679; PMCID: PMC7224781.

[3] Belluck P. Small number of COVID patients develop severe psychiatric symptoms. ht t p://www.nytimes.com/2020/12/28/health/covid-psychosis-mental.html; 2020, December 28.

[4] Watson CJ, Thomas RH, Solomon T, Michael BD, Nicholson TR, Pollak TA. COVID-19 and psychosis: real or delusional concern? Neurosci Lett 2021 Jan 10;741:135491. https://doi.org/10.1016/j.neulet.2020.135491. Epub 2020 Nov 18, 33 230366.

[5] Radua J, Ramella-Czaravo V, Joanndis JPA, Reichenberg A, Phihophashtaneet A, Amir T, et al. What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 2018 Feb;17(1):46–66. https://doi.org/10.1002/wps.20490. PMID: 29525556; PMCID: PMC5775150.

[6] Simon GE, Stewart C, Yarborough BJ, Lynch F, Coleman KJ, Beck A, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry 2018 Mar 1;75(3):254–60. https://doi.org/10.1001/jamapsychiatry.2017.4437. PMID: 29387976; PMCID: PMC5885951.

[7] Suviaiari J, Partti K, Vierio S, Viitanen S, Järenqvist J, et al. Mortality and its determinants in people with psychiatric disorder. Psychosom Med 2013 Jan;75(1):60–7. https://doi.org/10.1016/j.psymed.2012.12.006. Epub 2012 Dec 20, 32257961.

[8] Kulaga SS, Miller CWT. Viral respiratory infections and psychosis: A review of the literature and the implications of COVID-19. Neurosci Biobehav Rev 2021 Aug;127:520–30. https://doi.org/10.1016/j.neubiorev.2021.05.008. Epub 2021 May 31. PMID: 33926905.

[9] Brown E, Gray R, Lo Monaco S, O’Donoghue B, Nelson B, Thompson A, et al. The potential impact of COVID-19 on psychosis: a rapid review of contemporary epidemiologic and pandemic research. Schizophr Res 2020 Aug;222:79–87. https://doi.org/10.1016/j.schres.2020.05.005. Epub 2020 May 6. PMID: 32389615; PMCID: PMC7200363.

[10] Parra A, Juanes A, Losada CP, Alvarez-Sesmero S, Santana VD, Mariti J, et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. Psychiatry Res 2020 Sep 29;211:11254. https://doi.org/10.1016/j.psychres.2020.112545. Epub 2020 Jun 24. PMID: 3260930; PMCID: PMC7311137.

[11] Varrarari A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, et al. Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 2020 Oct;7(10):875–82. https://doi.org/10.1016/S2215-0366(20)30209-3. Epub 2020 Jun 25. Erratum in: Lancet Psychiatry. 2021 Jul 14; PMID: 32940341; PMCID: PMC7311461.

[12] Rogers JP, David AS. A longer look at COVID-19 and neuropsychiatric outcomes. Lancet Psychiatry 2021 May;8(5):351–2. https://doi.org/10.1016/S2215-0366(21)00075-0. Epub 2021 Apr 6. PMID: 33836149; PMCID: PMC8023693.

[13] Webster R, Holroyd S. Prevalence of psychosis symptoms in delirium. Psychosomatics. 2000 Nov-Dec;41(6):519–22. https://doi.org/10.1111/j.1520-4761.2004.00157.x.
Moll Mirza J, Ganguly A, Ostrovskaya A, Tusher A, Viswanathan R. Command suicidal behavior in COVID-19: a case report. J Psychiatr Pract 2021 Mar 52(2):131-6. https://doi.org/10.1097/YCH.0000000000002533. PMID: 36366820; PMCID: PMC8043329.

Nanasi A, Bassetti R, Radice A, et al. Anti-NMDA receptor encephalitis in a psychiatric COVID-19 patient: A case report. Brain Behav Immun 2020 Jul;87:179-81. https://doi.org/10.1016/j.bbi.2020.04.015. PMID: 32232747.

Parker C, Slan A, Shailer D, Critchfield A. A abrupt late-onset psychosis as a presentation of Coronavirus 2019 Disease (COVID-19): A longitudinal case report. J Psychiatr Pract 2021 Mar 52(2):131-6. https://doi.org/10.1097/YCH.0000000000002533. PMID: 36366820; PMCID: PMC8043329.

Sanos NF, Albo AP, Costa ID, Ferreira LP, Seco EH. First episode psychosis with delusional jealousy during SARS-CoV-2 infection: COVID-19 secondary psychosis or a trigger for a primary psychotic disorder? Prim Care Companion CNS Disord 2021;23(5). https://doi.org/10.4103/pcpc.pcdc.2021.210087. Published 2021 Sep 30.

Sen M, Yesilkuay U, Balcıoglu YH. SARS-CoV-2-associated first episode of acute mania with psychotic features. J Clin Neurosci 2021 May;87:29-31. https://doi.org/10.1016/j.jocn.2021.02.012. PMID: 33863529; PMCID: PMC8100463.

Smith CM, Komisar JR, Mourad A, Kincaid BR. COVID-19-associated brief psychotic disorder. BMJ Case Rep 2020 Aug 11(3); https://doi.org/10.1136/bcr-2020-240088. e240088. PMID: 32784244; PMCID: PMC7418683.

Tuna O, Salaman S, Darcin AE. COVID-19 pandemic in delusions: two cases. Psychiatr Danub 2020 Autumn;32(3):458-6. https://doi.org/10.24869/psd.2020.54.5. PMID: 33578564; PMCID: PMC7643772.

Vega A, Saleem A, Dharmaraj D, Afzal Q. COVID-19 diagnostic difficulties and acute psychosis. Br J Med Pract 2020;13(1). https://doi.org/10.7326/M20-6976. Epub 2021 Jan 22. PMID: 33481642; PMCID: PMC7643772.

Zain SM, Muthukangaran P, Rahman N. Excited Catatonia - A Delayed Neuropsychiatric Complication of COVID-19 Infection. Cureus 2021 Mar 15;13(3):e9189. https://doi.org/10.7759/cureus.13891. PMID: 33880247; PMCID: PMC8345148.

Zinn SA, Morariu CC, Wolters MA, Hafner H, Gockel I, Giel S. Depression and suicide attempts during the COVID-19 pandemic. Schizophr Bull 2021;47(1):153-6. https://doi.org/10.1093/schbul/sbaa128. Epub ahead of print. PMID: 33906867; PMCID: PMC8066508.
[77] Keepers GA, Fochtman LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2020;177(9):868–72. https://doi.org/10.1176/appi.ajp.2020.177901.

[78] Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes 2014 Apr 23;7:264. https://doi.org/10.1186/1756-0500-7-264. PMID: 24758689; PMCID.

[79] Iqbal Y, Al Abdulla MA, Albrahim S, Latoo J, Kumar R, Haddad PM. Psychiatric presentation of patients with acute SARS-CoV-2 infection: a retrospective review of 50 consecutive patients seen by a consultation-liaison psychiatry team. BJPsych Open 2020;6(5):e109. Published 2020 Sep 10, https://doi.org/10.1192/bjo.2020.85.